tralesinidase alfa
Recombinant proteinexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started Nov 30, 2022 (NCT05492799)
Timeline
No events for the selected filters.
Indications
Approved for
Mechanism of action
- Alpha-N-acetylglucosaminidaseSupplementation
NAGLU supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05492799 | Phase 4 | Nov 30, 2022 | Allievex Corporation |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Allievex Corporation | For profit | 1 | 1 | 1 | 2022 |
1 organizations
Page 1 / 1